NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)
Grant Opportunity Analysis
The National Institutes of Health (NIH) has announced a funding opportunity titled "NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)." This initiative invites applications to leverage the NHLBI-funded TransOmics for Precision Medicine (TOPMed) program to generate integrated genetic and multi-omics data aimed at uncovering the molecular mechanisms underlying Heart, Lung, Blood, and Sleep (HLBS) disorders. The program is significant for advancing the understanding of genetic factors contributing to HLBS diseases, with a focus on transitioning from genetic associations to molecular insights, potentially utilizing artificial intelligence and machine learning tools. No direct funding will be provided; instead, successful applicants will gain access to omics assay resources and are expected to contribute data to public NIH-designated controlled-access databases. The application period opens on October 6, 2025, and closes on May 8, 2028, with a maximum project duration of three years. Interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
Eligible Applicants
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.